Bench to bedside: Nitric oxide in emergency medicine

Academic Emergency Medicine

Volumn 7, Issue 3, 2000, Pages 285-293

  Lopez, Bernard L ^a   Christopher, Theodore A ^a   Griswold, Sharon K ^a   Ma, Xin Liang ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Emergency medicine; Nitric oxide; Review

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; THIOUREA DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1;

ASTHMA; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR DISEASE; EMERGENCY MEDICINE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; LEUKOCYTE ADHERENCE; LUNG DISEASE; PHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEPSIS; SICKLE CELL ANEMIA; THROMBOCYTE AGGREGATION; VASODILATATION; VASOMOTOR REFLEX;

EID: 0034007032     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2000.tb01081.x     Document Type: Review

References (108)

1. Rappeport JM, Bunn HF. Bone marrow failure: aplastic anemia and other primary bone marrow disorders. In: Braunwald E, Isselbacher KJ, Petersdorf RG, et al. (eds). Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 1994.
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987; 84:9265-9.
3. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM (ed). Mechanisms of Vasodilation. New York: Raven Press, 1988, pp 401-14.
4. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2:1057-8.
5. de Graaf JC, Banga JD, Moncada S, Palmer RMJ, de Groot PG, and Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-90.
6. Moilanen E, Vuorinen P, Kankaareranta H, Metsa-Ketela T, and Vapaatalo H. Inhibition by nitric oxide donors of human polymorphonuclear leukocyte functions. Br J Pharmacol. 1993; 109:852-8.
7. Kubes P, Suzuki M, and Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991; 88:4651-5.
8. Ma XL, Lefer AM, and Zipkin RE. S-Nitroso-N-acetylpenicillamine is a potent inhibitor of neutrophil-endothelial interaction. Endothelium. 1993; 1:31-9.
9. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994; 298:249-58.
10. Moore KL, Andreoli SP, Bang NU, et al. Endotoxin enhances tissue factor and supresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987; 79:124-30.
11. Okusawa S, Gelfand JA, Connolly RJ, et al. Interleukin-1 induces a shock like state in rabbits. J Clin Invest. 1988; 81: 1162-72.
12. Cobb JP, Danner RL. Nitric oxide and septic shock. JAMA. 1996; 275:1192-6.
13. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med. 1994; 120:227-37.
14. Murad F. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA. 1996; 276:1189-92.
15. Murad F. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA. 1996; 276:1189-92.
16. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol Lung Cell Mol Physiol. 1995; 268:L699-L722.
17. Beckman JS. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann N Y Acad Sci. 1994; 738:69-75.
18. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986; 250:H822-H827.
19. Rubbo H, Denicola A, Radi R. Peroxynitrite inactivates thiol-containing enzymes of Trypanosoma cruzi energetic metabolism and inhibits cell respiration. Arch Biochem Biophys. 1994; 308:96-102.
20. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol Lung Cell Mol Physiol. 1993; 265:L555-L564.
21. Hu P, Ischiropoulos H, Beckman JS, Matalon S. Peroxynitrite inhibition of oxygen consumption and sodium transport in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol. 1994; 266:L628-L634.
22. Haddad IY, Beckman JS, Garver RI, Matalon S. Structural and functional alterations of surfactant protein A by peroxynitrite. Chest. 1994; 105(suppl):84S-84S.
23. Ishida H, Ichimori K, Hirota Y, Fukahori M, Nakazawa H. Peroxynitrite-induced cardiac myocyte injury. Free Radic Biol Med. 1996; 20:343-50.
24. Carreras MC, Pargament GA, Catz SD, Poderoso JJ, Boveris A. Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst of human neutrophils. FEBS Lett. 1994; 341:65-8.
25. Rodenas J, Mitjavila MT, Carbonell T. Simultaneous generation of nitric oxide and superoxide by inflammatory cells in rats. Free Radic Biol Med. 1995; 18:869-75.
26. Das DK. Cellular, biochemical, and molecular aspects of reperfusion injury. Introduction. Ann NY Acad Sci. 1994; 723: xiii-xxvi.
27. Zimmerman BJ, Granger DN. Mechanisms of reperfusion injury. Am J Med Sci. 1994; 307:284-92.
28. Maynard C, Weaver WD, Litwin PE, et al. Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention project). Am J Cardiol. 1993; 72:877-82.
29. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91:1872-85.
30. Lucchesi BR. Cardiac reperfusion injury. In: Zikria BA, Oz MO, Carlson RW (eds). Reperfusion Injury and Clinical Capillary Leak Syndrome. Armonk, NY: Futura Publishing Company, 1994, pp 171-202.
31. Duran WN, Silva MBJ, Ferrante RJ. Microcirculatory dysfunction in ischemia: reperfusion injury. In: Zikria BA, Oz MO, Carlson RW (eds). Reperfusion Injuries and Clinical Capillary Leak Syndrome. Armonk, NY: Futura Publishing Company, 1994, pp 145-69.
32. Das DK, Maulik N. Antioxidant effectiveness in ischemia-reperfusion tissue injury. Methods Enzymol. 1994; 233:601-10.
33. Bienvenu K, Granger DN. Leukocyte adhesion in ischemia/reperfusion. Blood Cells. 1993; 19:279-89.
34. Smith CW. Leukocyte-endothelial cell interactions. Semin Hematol. 1993; 30(suppl 4):45-55.
35. Provost P, Lam JYT, Lacoste L, Merhi Y, Waters D. Endothelium-derived nitric oxide attenuates neutrophil adhesion to endothelium under arterial flow conditions. Arterioscler Thromb Vasc Biol. 1994; 14:331-5.
36. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991; 88:4651-5.
37. Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion in dogs. Circulation. 1993; 88:2337-50.
38. Egdell RM, Siminiak T, Sheridan DJ. Modulation of neutrophil activity by nitric oxide during acute myocardial ischaemia and reperfusion. Basic Res Cardiol. 1994; 89:499-509.
39. Fukuda H, Sawa Y, Kadoba K, Taniguchi K, Shimazaki Y, Matsuda H. Supplement of nitric oxide attenuates neutrophil-mediated reperfusion injury. Circulation. 1995; 92(suppl):413-6.
40. Kupatt C, Zahler S, Seligmann C, Massoudy P, Becker BF, Gerlach E. Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia. J Mol Cell Cardiol. 1996; 28:643-54.
41. Lefer AM, Siegfried MR, Ma XL. Protection of ischemia-reperfusion injury by sydnonimine NO donors via inhibition of neutrophil-endothelium interaction. J Cardiovasc Pharmacol. 1993; 22(suppl 7):S27-S33.
42. Sato H, Zhao ZQ, McGee DS, Williams MW, Hammon JW Jr., Vinten-Johansen J. Supplemental L-arginine during cardioplegic arrest and reperfusion avoids regional postischemic injury. J Thorac Cardiovasc Surg. 1995; 110:302-14.
43. Weyrich AS, Ma XL, Lefer AM. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation. 1992; 86:279-88.
44. Li XS, Uriuda Y, Wang QD, Norlander R, Sjoquist PO, Pernow J. Role of L-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart. Acta Physiol Scand. 1996; 156:37-44.
45. Katusic ZS. Nitric oxide: regulator of P-selectin expression. Gastroenterology. 1994; 107:1199-201.
46. Kanwar S, Kubes P. Nitric oxide is an antiadhesive molecule for leukocytes. New Horizons. 1995; 3:93-104.
47. Racknow EC, Astiz ME. Pathophysiology and treatment of septic shock. JAMA. 1994; 226:548-54.
48. Millar GM, Thiemermann C. NO in septic shock. In: Googorski MS, Gross S (eds). Nitric Oxide and the Kidney. Physiology and Pathophysiology. New York: Chapman and Hall, 1997, pp 271-306.
49. Thiemermann C. Nitric oxide and septic shock. Gen Pharmacol. 1997; 29:159-66.
50. Kilbourn R. Nitric oxide and shock. Dis Mon. 1997; 43: 281-348.
51. Ceppi ED, Smith FS, Titheradge MA. Nitric oxide, sepsis, and liver metabolism. Biochem Soc Trans. 1997; 25:929-34.
52. Gomez-Jimenez J, Salgado A, Mourelle M, et al. Nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med. 1995; 23:253-7.
53. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991; 43:109-42.
54. Thitheradge M. Nitric oxide in septic shock. Biochem Biophysic Acta. 1999; 1411:437-55.
55. Knowles RG, Moncada S. Nitric oxide as a signal in blood vessels. Trends Biochem Sci. 1992; 17:399-402.
56. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992; 105:575-80.
57. Haynes WG, Noon JP, Walker BR, et al. L-NMMA increases blood pressure in healthy humans. Lancet. 1993; 342: 931-2.
58. Petros A, Lamb G, Bennett D, et al. Effects of nitric oxide synthase inhibitor on humans with septic shock. Cardiovasc Res. 1994; 28:34-9.
59. Schneider F, Lutun P, Temple JD, et al. Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observation. Intensive Care Med. 1992; 18:309-11.
60. Kilbourn RG, Gross SS, Jubran A, et al. N-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA. 1990; 87:3629-32.
61. Strand OA, Leone AM, Giercksky KE, et al. NG-monomethyl-L-arginine improves in a pig model of abdominal sepsis. Crit Care Med. 1998; 26:1490-9.
62. Avontuur JAM, Biewenga M, Buijk SLCE, et al. Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock. Shock. 1998; 9:451-4.
63. Werra ID, Jaccard C, Corradin SB, et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med. 1997; 25:607-13.
64. Cobb JP, Cunnion RE, Danner RL. Nitric oxide as a target for therapy in septic shock. Crit Care Med. 1993; 21:1261-2.
65. Freeman BD, Cobb JP. Nitric oxide synthase as a therapeutic target in sepsis - more questions than answers? Crit Care Med. 1998; 26:1446-7.
66. Perella MAA, Hsieh CW, Lee WS, et al. Arrest of endotoxin-induced hypotension by transforming growth factor-1. Proc Natl Acad Sci USA. 1996; 93:2054-9.
67. Roselet A, Feihl F, Markert M, et al. Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med. 1998; 157:162-70.
68. Kobzik L, Bred DS, Lowenstein CJ, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol. 1993; 9: 371-7.
69. Gaston B, Drazen J, Loscalzo J, et al. State of the art: the biology of nitrogen oxides in the airways. Am J Respir Crit Care Med. 1994; 149:538-51.
70. Stamler J, Loh E, Roddy M, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994; 89:2035-40.
71. Blitzer M, Loh E, Roddy M, et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol. 1996; 28:591-6.
72. Frostell C, Blomqvist H, Hedenstierna G, et al. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology. 1993; 78:427-35.
73. Alving K, Weitzberg E, Lundberg JM. Increasing amounts of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993; 6:1268-302.
74. Kharitonov SA, Yates D, Logan-Sinclair R, Shinebourne A, Barnes PJ. Endogenous nitric oxide is increased in the exhaled air of asthmatic patients. Lancet. 1994; 343:146-7.
75. Kharitonov SA, O'Connor BJ, Evans DJ, Barnes PJ. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med. 1995; 151:1894-9.
76. Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Crit Care Med. 1995; 152:892-6.
77. Kuo HP, Liu S, Barnes PJ. The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea pig airways. Eur J Pharmacol. 1992; 221:385-8.
78. Hulks G, Warren PM, Douglas NJ. The effect of inhaled nitric oxide on bronchomotor tone in the normal human [abstract]. Am Rev Respir Dis. 1993; 139:A350.
79. Stretton D. Nonadrenergic, noncholinergic neural control of the airways. Clin Exp Pharmacol Pathol. 1991; 18:675-84.
80. Belvisi MG, Ward JK, Mitchell JK, Barnes PJ. Nitric oxide as a neurotransmitter in human airways. Arch Intern Pharmacodyn. Ther 1995; 329:97-110.
81. Bigatello IM, Zapol WM. New approaches to acute lung injury. Br J Anaesth. 1996; 77:99-109.
82. Lunn RJ. Inhaled nitric oxide therapy. Mayo Clin Proc. 1995; 70:247-55.
83. Toncy E, Francoeur M, Blaise G. Inhaled nitric oxide: clinical applications, indications, and toxicology. Can J Anaesth. 1997; 44:973-88.
84. Krafft P, Fridrich P, Fitzgerald RD, et al. Effectiveness of nitric oxide inhalation in septic ARDS. Chest. 1996; 109:486-93.
85. Manktelow C, Bigatello LM, Hess D, et al. Physiological determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology. 1994; 80:761-70.
86. Bloomfield GL, Holloway S, Fisher BJ, et al. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit Care Med. 1997; 25:584-93.
87. Chollet-Martin S, Gatacel C, Kermarrec N, et al. Alveolar neutrophil functions and cytokine levels in patients with adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med. 1996; 153:985-90.
88. Sanama CM, Diaby M, Fellahi JI, et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology. 1995; 83:56-65.
89. Bigatello LM, Hurford WE, Kacmarek RM, et al. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome: effects on pulmonary hemodynamics and oxygenation. Anesthesiology. 1994; 80:761-70.
90. Benzing A, Brautigam P, Geiger K, et al. Inhaled nitric oxide reduces pulmonary transvascular albumin flux in patients with acute lung injury. Anesthesiology. 1995; 83:1153-61.
91. Garat C, Jayr C, Eddahibi S, et al. Effects of inhaled nitric oxide on inhibition of endogenous nitric oxide formation on hyperoxic lung injury. Am J Respir Crit Care Med. 1997; 155: 1957-64.
92. McElroy M, Wiener-Kronish J, Miyazaki H, et al. Nitric oxide attenuates lung endothelial injury caused by sublethal hyperoxia in rats. Am J Physiol. 1997; 272:L631-L638.
93. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in lungs of patients with pulmonary hypertension. N Engl J Med. 1995; 333:214-21.
94. Channick R, Hoch R, Newhart J, et al. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am J Respir Crit Care Med. 1994; 149:811-4.
95. Gerlach H, Rossaint R, Pappert D, et al. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest. 1993; 23:499-502.
96. Dinh-Xuan A, Higenbottam T, Clelland C, et al. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991; 324: 1539-47.
97. Marceira-Rodriquez L, Gernsheimer J, Osborn HH. Emergency management of sickle cell anemia. Hosp Physician. 1985; March:14-29.
98. Konotey-Ahulu FID. The sickle cell diseases: clinical manifestations including the "sickle crisis." Arch Intern Med. 1974; 133:611-9.
99. Ballas SK, Larner J, Smith ED, Surrey S, Schwartz E, Rappaport EF. Rheologic predictors of the severity of the painful sickle cell crisis. Blood. 1988; 4:1216-23.
100. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288:373-6.
101. Mosseri M, Bartlett-Pandite AN, Wenc K, Isner JM, Weinstein R. Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J. 1993; 126:338-46.
102. Rees DC, Cervi P, Grimwade D, et al. The metabolites of nitric oxide in sickle-cell disease. Br J Haematol. 1995; 91:834-7.
103. Lopez BL, Barnett J, Christopher TA, Ballas SK, Davis-Moon L, Ma XL. Nitric oxide metabolite levels in acute vasoocclusive sickle cell crisis patients in the emergency department. Acad Emerg Med. 1996; 3:1098-103.
104. Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increases oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest. 1997; 100: 1193-8.
105. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology. 1997; 87: 988-90.
106. Ketcham EM, Cairns CB: Hemoglobin-based oxygen carriers: development and clinical potential. Ann Emerg Med. 1999; 33:326-37.
107. Veeramachaneni NK, Harken AH, Cairns CB: Clinical implications of hemoglobin as a nitric oxide carrier. Arch Surg. 1999; 134:434-7.
108. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergency surgery. J Am Coll Surg. 1998; 187:113-20.